Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments

Polychronopoulos, Georgios; Papagiannis, Achilleas; Τζιόμαλος, Κωνσταντίνος

doi:10.1080/17512433.2023.2174524

Expert Review of Clinical Pharmacology

2023

DOI: 10.1080/17512433.2023.2174524

|View full text |Cite

Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments

Georgios Polychronopoulos

Achilleas Papagiannis

Κωνσταντίνος Τζιόμαλος

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 Novel agents including antisense oligonucleotides and small interfering RNA targeting apolipoprotein(a) have been shown to reduce Lp(a) levels, and there are currently ongoing clinical trials to show their efficacy to prevent recurrent events in adults with ASCVD without severe kidney disease (NCT04023552 and NCT05581303). 4 , 5 It is currently unclear whether high Lp(a) levels confer an increased risk for recurrent ASCVD events specifically in adults with CKD. If high Lp(a) levels are associated with an increased risk for recurrent ASCVD events in adults with CKD, this may represent an opportunity for ASCVD risk reduction in this high-risk population through novel Lp(a)-lowering therapies.…”

mentioning

confidence: 99%

Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

et al. 2023

View full text Add to dashboard Cite

mentioning

confidence: 99%

Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

et al. 2023

View full text Add to dashboard Cite

Biomarker-Guided Dietary Supplementation: A Narrative Review of Precision in Personalized Nutrition

Pokushalov,

Ponomarenko,

Shrainer

et al. 2024

Nutrients

View full text Add to dashboard Cite

Background: Dietary supplements (DS) are widely used to address nutritional deficiencies and promote health, yet their indiscriminate use often leads to reduced efficacy, adverse effects, and safety concerns. Biomarker-driven approaches have emerged as a promising strategy to optimize DS prescriptions, ensuring precision and reducing risks associated with generic recommendations. Methods: This narrative review synthesizes findings from key studies on biomarker-guided dietary supplementation and the integration of artificial intelligence (AI) in biomarker analysis. Key biomarker categories—genomic, proteomic, metabolomic, lipidomic, microbiome, and immunological—were reviewed, alongside AI applications for interpreting these biomarkers and tailoring supplement prescriptions. Results: Biomarkers enable the identification of deficiencies, metabolic imbalances, and disease predispositions, supporting targeted and safe DS use. For example, genomic markers like MTHFR polymorphisms inform folate supplementation needs, while metabolomic markers such as glucose and insulin levels guide interventions in metabolic disorders. AI-driven tools streamline biomarker interpretation, optimize supplement selection, and enhance therapeutic outcomes by accounting for complex biomarker interactions and individual needs. Limitations: Despite these advancements, AI tools face significant challenges, including reliance on incomplete training datasets and a limited number of clinically validated algorithms. Additionally, most current research focuses on clinical populations, limiting generalizability to healthier populations. Long-term studies remain scarce, raising questions about the sustained efficacy and safety of biomarker-guided supplementation. Regulatory ambiguity further complicates the classification of supplements, especially when combinations exhibit pharmaceutical-like effects. Conclusion: Biomarker-guided DS prescription, augmented by AI, represents a cornerstone of personalized nutrition. While offering significant potential for precision and efficacy, advancing these strategies requires addressing challenges such as incomplete AI data, regulatory uncertainties, and the lack of long-term studies. By overcoming these obstacles, clinicians can better meet individual health needs, prevent diseases, and integrate precision nutrition into routine care.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments

Cited by 2 publications

References 28 publications

Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

Biomarker-Guided Dietary Supplementation: A Narrative Review of Precision in Personalized Nutrition

Contact Info

Product

Resources

About